Dosage and administration
Moisten face with water. Dispense product onto fingertips and massage over face. Rinse with water. Avoid direct contact with eyes. In case of contact with eyes, flush thoroughly with water.
Moisten face with water. Dispense product onto fingertips and massage over face. Rinse with water. Avoid direct contact with eyes. In case of contact with eyes, flush thoroughly with water.
DRUG FACTS
Salicylic Acid (2%)
Acne Treatment
Treats Acne
For external use only.
Using other topical acne medications at the same time or immediately following use of this product may increase dryness or irritation of the skin. If this occurs only one medication should be used unless directed by a doctor.
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Moisten face with water. Dispense product onto fingertips and massage over face. Rinse with water. Avoid direct contact with eyes. In case of contact with eyes, flush thoroughly with water.
Water, Glycerin, Stearic Acid, Sodium C14-16 Olefin Sulfonate, Propylene Glycol, Glycereth-18 Ethylhexanoate, Cocamidopropyl Betaine, PEG-100 Stearate, Glyceryl Stearate, Acrylates/Aminoacrylates/C10-30 Alkyl PEG-20 Itaconate Copolymer, Camellia Sinensis Leaf Extract+, Glycereth-18, Sodium Hydroxide, Betaine, Isopropyl Alcohol, Trideceth-50, PPG-2 Methyl Ether, Phenethyl Alcohol, Methylisothiazolinone, Fragrance, Green 5, Yellow 5, Red 33, Red 4, Blue 1.
1-866-912-9867
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 562600 | salicylic acid 2 % Medicated Liquid Soap | PSN | 1 |
| 1039716 | St. Ives 2 % Medicated Liquid Soap | PSN | 1 |
| 1039716 | salicylic acid 20 MG/ML Medicated Liquid Soap [St. Ives Blemish & Blackhead Control] | SBD | 1 |
| 562600 | salicylic acid 20 MG/ML Medicated Liquid Soap | SCD | 1 |
| 562600 | salicylic acid 2 % Facial Cleanser Toner | SY | 1 |
| 562600 | salicylic acid 2 % Facial Scrub | SY | 1 |
| 562600 | salicylic acid 2 % Medicated Liquid Soap | SY | 1 |
| 1039716 | St. Ives Blemish & Blackhead Control 2 % Medicated Liquid Soap | SY | 1 |
| 1039716 | St. Ives Blemish & Blackhead Control 20 MG/ML Medicated Liquid Soap | SY | 1 |
| 1039716 | St. Ives Green Tea 2 % Medicated Liquid Soap | SY | 1 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 6c13b22c-b3ba-4127-b768-0132dd5ab0d1 | Product name | 1 | 20230829 |
| d1c9d1af-bddd-448d-86f7-69052b7d5b47 | Product name | 1 | 20220627 |
| dea2eded-d1e7-46bb-9a3d-f8dc20de6277 | Product name | 1 | 20190408 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 12488-0700-6 | 2019-10-29 | C162847 | 48780-1 | 960f7f55-d481-8e05-e053-dbdaa90a074a | ST. Ives ® Naturally Clear CREAM CLEANSER GREEN TEA |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 12488-0700-6 | ST. IVES NATURALLY CLEAR SKIN GREEN TEA FACIAL | 170 g in 1 TUBE | SOAP | 170 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 12488-0700 | ST. IVES NATURALLY CLEAR SKIN GREEN TEA FACIAL (SALICYLIC ACID) SOAP [ALBERTO-CULVER USA INC.] | 1 | Legacy NDC, 1 package rows | 20120103_1a5f12bd-a16b-4ea0-b533-dbd2ff6c8034.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Salicylic Acid | ACTIVE INGREDIENT | O414PZ4LPZ | 1 | |
| Salicylic Acid | ACTIVE MOIETY | O414PZ4LPZ | 1 | |
| Betaine | INACTIVE INGREDIENT | 3SCV180C9W | 1 | |
| Cocamidopropyl Betaine | INACTIVE INGREDIENT | 5OCF3O11KX | 1 | |
| D&C Green No. 5 | INACTIVE INGREDIENT | 8J6RDU8L9X | 1 | |
| D&C Red No. 33 | INACTIVE INGREDIENT | 9DBA0SBB0L | 1 | |
| Fd&C Blue No. 1 | INACTIVE INGREDIENT | H3R47K3TBD | 1 | |
| Fd&C Red No. 4 | INACTIVE INGREDIENT | X3W0AM1JLX | 1 | |
| Fd&C Yellow No. 5 | INACTIVE INGREDIENT | I753WB2F1M | 1 | |
| Glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| Glyceryl Monostearate | INACTIVE INGREDIENT | 230OU9XXE4 | 1 | |
| Green Tea Leaf | INACTIVE INGREDIENT | W2ZU1RY8B0 | 1 | |
| Isopropyl Alcohol | INACTIVE INGREDIENT | ND2M416302 | 1 | |
| Methylisothiazolinone | INACTIVE INGREDIENT | 229D0E1QFA | 1 | |
| PEG-100 Stearate | INACTIVE INGREDIENT | YD01N1999R | 1 | |
| Phenylethyl Alcohol | INACTIVE INGREDIENT | ML9LGA7468 | 1 | |
| Propylene Glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| Sodium C14-16 Olefin Sulfonate | INACTIVE INGREDIENT | O9W3D3YF5U | 1 | |
| Sodium Hydroxide | INACTIVE INGREDIENT | 55X04QC32I | 1 | |
| Stearic Acid | INACTIVE INGREDIENT | 4ELV7Z65AP | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 12488-0700 | 12488-0700-6 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRACAUDAL | ADJ PH | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SHAMPOO / TOPICAL | 8 %w/w | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / URETHRAL | ADJ PH | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SPONGE / TOPICAL | 40 %w/w | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / PARENTERAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / SUBCUTANEOUS | ADJ PH | ||
| Stearic Acid | STEARIC ACID | 4ELV7Z65AP | CREAM / VAGINAL | 1088 mg | ||
| Glyceryl Monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET, EXTENDED RELEASE / ORAL | 529 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| PEG-100 Stearate | PEG-100 MONOSTEARATE | YD01N1999R | LOTION / TOPICAL | 1 %w/w | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / SUBCUTANEOUS | 31.45 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION / SUBCUTANEOUS | ADJ PH | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET / ORAL | 64 mg | ||
| Glyceryl Monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | EMULSION / ORAL | NA | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, DELAYED RELEASE / ORAL | 36 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | PASTE / DENTAL | 0.5 %w/w | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SUPPOSITORY / VAGINAL | 252 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRAVENOUS | 456 mg | ||
| Fd&C Blue No. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE, DELAYED RELEASE / ORAL | 2 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE / ORAL | 60 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / INTRAVENOUS | 5 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / EPIDURAL | ADJ PH | ||
| Fd&C Blue No. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET, FILM COATED / ORAL | 0.16 mg | ||
| D&C Green No. 5 | D&C GREEN NO. 5 | 8J6RDU8L9X | SOLUTION / ORAL | NA | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | LIQUID / INTRAMUSCULAR | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAMUSCULAR | 78 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CAPSULE, EXTENDED RELEASE / ORAL | 265 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRA-AMNIOTIC | ADJ PH | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SYSTEM / TOPICAL | 18144 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION / AURICULAR (OTIC) | ADJ PH | ||
| Stearic Acid | STEARIC ACID | 4ELV7Z65AP | TABLET, CHEWABLE / ORAL | 180 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRATHECAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / RESPIRATORY (INHALATION) | 8 %w/v | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | LIQUID / RESPIRATORY (INHALATION) | 10 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| Fd&C Yellow No. 5 | FD&C YELLOW NO. 5 | I753WB2F1M | CONCENTRATE / BUCCAL | NA | ||
| Fd&C Blue No. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SOAP / TOPICAL | 0.01 %w/w | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / PARENTERAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRATUMOR | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION / INTRAVENOUS | ADJ PH | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRA-ARTERIAL | 176 mg | ||
| Fd&C Yellow No. 5 | FD&C YELLOW NO. 5 | I753WB2F1M | TABLET, FILM COATED / ORAL | 1.68 mg | ||
| Fd&C Blue No. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SHAMPOO / TOPICAL | 0.75 %w/w | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION, CONCENTRATE / INTRAVENOUS | 50.33 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRAMUSCULAR | 176 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SPRAY, METERED / NASAL | ADJ PH | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, COATED / ORAL | 16 mg | ||
| Isopropyl Alcohol | ISOPROPYL ALCOHOL | ND2M416302 | SOLUTION / TOPICAL | 40 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SYRUP / ORAL | 71 mg/5ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION, CONCENTRATE / ORAL | 200 mg/1ml | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / SOFT TISSUE | ADJ PH | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / INTRAVENOUS | 4000 mg | ||
| Fd&C Blue No. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET, SUGAR COATED / ORAL | NA | ||
| Fd&C Yellow No. 5 | FD&C YELLOW NO. 5 | I753WB2F1M | SYRUP / ORAL | 0.1 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | OINTMENT, AUGMENTED / TOPICAL | 0.11 %w/w | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SPRAY / NASAL | ADJ PH | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| b2a9c916-0244-4fc5-8569-b2aeb7eade7c | 1a5f12bd-a16b-4ea0-b533-dbd2ff6c8034 | 2011-05-06 | Warnings | b2a9c916-0244-4fc5-8569-b2aeb7eade7c 1a5f12bd-a16b-4ea0-b533-dbd2ff6c8034 |
Adverse event summaries are temporarily unavailable. Other product information remains available.